ADC Therapeutics SA Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
ADC Therapeutics SA (ADCT) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$5.00K, a 103.11% decline year-over-year.
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $161.00K.
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$43.00K, a 148.31% decline year-over-year.
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $89.00K.
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $305.00K.
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$83.00K, a 145.11% decline from fiscal 2023.
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $184.00K.
- ADC Therapeutics SA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$208.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$5.00K 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $305.00K 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $330.00K 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $324.00K 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $161.00K 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$83.00K 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $260.00K 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$31.00K 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$43.00K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $184.00K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $32.00K 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $150.00K 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $89.00K 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$208.00K 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |